报告期内，公司主营业务保持稳健发展，为巩固在产业领域内的长期竞争优势，公司保持原有几大技术 平台的先进性之外，持续加大对新技术平台的战略性投入，同时国内外市场及注册证书等拓展，海外分 子公司的布局致使费用增加。 安旭生物(688075.SH)发布2025年年度业绩预告，预计2025年年度实现归属于母公司所有者的净利润 7100万元到8500万元，与上年同期(法定披露数据)相比，将减少10,729.53万元到12,129.53万元，同比减 少55.80%到63.08%。 ...

证券日报网讯 1月30日，科兴制药发布公告称，公司预计 2025 年年度实现归属于母公司所有者的净利 润为 13，500 万元至 17，500万元，与上年同期（法定披露数据）相比，将增加 10，352 万元至 14， 352 万元，同比增加 328.83%至 455.89%。 （文章来源：证券日报） ...

Core Viewpoint - ST Xiangxue expects a net profit loss of 635 million to 934 million yuan for the year 2025, primarily due to intensified market competition, liquidity crisis, high financial costs, and asset impairment [1] Group 1: Financial Performance - The company anticipates a significant loss in net profit for 2025, ranging from 635 million to 934 million yuan [1] - Factors affecting performance include increased market competition, liquidity issues, high financial expenses, and asset impairment [1] Group 2: Business Operations - Despite short-term operational challenges, the overall business situation remains normal, and the company aims to enhance profitability for sustainable operations [1] - The company has made significant progress in innovative drug research and development [1] Group 3: R&D Achievements - The company's subsidiary, Xiangxue Life Science Technology, has received clinical approval for the TCR-T cell therapy product "XLS-103 Injection" for treating advanced non-small cell lung cancer and advanced pancreatic cancer with specific genetic mutations [1] - This approval marks the sixth and seventh clinical trial permits obtained by Xiangxue Life Science based on its core TCR-T cell therapy technology and R&D platform [1] - The company has established a comprehensive platform covering antigen peptide discovery, TCR affinity optimization, and full-process development, with three TCR-T products targeting various solid tumors [1]

Core Viewpoint - The company ST Ningke announced a joint venture with Hangzhou Hecarbon to establish Ningxia Zhongke Hecarbon Chuangwu Biotechnology Co., Ltd. with a registered capital of 20 million yuan [1] Group 1: Joint Venture Details - The company will contribute 10.2 million yuan in cash, holding a 51% stake in the joint venture [1] - The board of directors has approved the proposal, which does not require shareholder approval and does not constitute a related party transaction or a major asset restructuring [1] Group 2: Strategic Intent - The investment aims to introduce algal oil fatty acid products, enhance capacity utilization, and reduce the risk associated with a single main product [1] Group 3: Future Considerations - There is uncertainty regarding the approval of the subsidiary's registration, and future operations may face risks related to the macroeconomic environment and market development [1]

Core Viewpoint - Boya Bio (300294.SZ) forecasts a significant decline in net profit for the fiscal year 2025, projecting a net profit attributable to shareholders of between 105 million yuan and 137 million yuan, representing a year-on-year decrease of 65.62% to 73.55% [1] Financial Performance - The company anticipates a net loss of between 7.5 million yuan and 15 million yuan after excluding non-recurring gains and losses [1]

Core Viewpoint - Boya Bio (300294.SZ) has disclosed its earnings forecast for the year 2025, indicating a significant decline in net profit attributed to shareholders, with expectations of a decrease between 65.62% to 73.55% compared to the previous year [1] Financial Performance - The company anticipates a net profit of between 105 million to 137 million yuan for 2025 [1] - Excluding non-recurring gains and losses, the company expects a net loss ranging from 7.5 million to 15 million yuan [1]

Core Viewpoint - Shenzhou Cell is expected to report a net loss attributable to shareholders of the parent company for the year 2025, ranging from -580 million to -520 million yuan, compared to the previous year [1] Group 1: Financial Performance - The company anticipates a significant decline in sales revenue due to ongoing healthcare cost control policies and multiple price reductions of its core product, Anjiah [1] - Overall operating revenue is expected to decrease compared to the same period last year [1] Group 2: Investment and Expenses - To facilitate market access and channel development for newly approved products, the company has increased upfront commercialization investments, including academic promotion and sales team formation, leading to a noticeable rise in sales expenses in the short term [1] - The company maintains a high level of research and development investment, with several ongoing projects entering critical confirmatory clinical trial stages during the reporting period [1]

Core Viewpoint - Changchun Gaoxin (000661) is expected to report a significant decline in net profit for the year 2025, with projections indicating a drop of 91.48% to 94.19% compared to the previous year [1] Financial Performance - The company anticipates a net profit ranging from 150 million to 220 million yuan for 2025 [1] - The net profit excluding non-recurring gains and losses is projected to be between 437 million and 507 million yuan, reflecting a year-on-year decrease of 82.09% to 84.56% [1]

北京商报讯（记者 王寅浩 宋雨盈）1月30日，华熙生物发布2025年业绩预告，预计2025年实现归属于母 公司所有者的净利润2.7亿—3.2亿元，同比增加54.93%—83.63%。预计实现归属于母公司所有者的扣除 非经常性损益的净利润1.67亿—2.17亿元，同比增加55.68%—102.29%。 ...

1月30日，华熙生物发布2025年年度业绩预增公告。公告显示，公司预计2025年实现归属于母公司所有 者的净利润2.70亿元至3.20亿元，同比增长54.93%到83.63%；扣除非经常性损益后的净利润1.67亿元至 2.17亿元，同比增长55.68%到102.29%。公司盈利能力实现显著提升，体现出经营质量持续改善的发展 成效。 2025年业绩增长是华熙生物组织优化、业务聚焦、科技创新与数字化赋能协同发力的综合成果，也是长 期坚持高质量发展和核心能力建设的阶段性体现。未来，公司将继续坚持以科技创新为核心，以合成生 物技术和产业化平台为支撑，持续夯实长期竞争优势，推动经营质量和可持续发展能力稳步提升。 财经频道更多独家策划、专家专栏，免费查阅>> 责任编辑：山上 在业务运营层面，华熙生物以专业化聚焦发展方向，持续优化业务结构和资源配置。通过加强供应链协 同管理、推进库存结构优化，将更多资源投入到具备长期竞争优势的核心领域。2025年销售费用同比下 降超过30%，在收入承压的背景下实现盈利能力持续改善。 在研发和科技创新层面，华熙生物基于糖类物质在细胞分化与信号机制中的关键作用，围绕细胞外基 质、细胞间通讯、细 ...